This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Indications

Authoring team

The indications for neuroleptics are:

  • schizophrenia - relatively less effective in the simple form, and in withdrawn or depressed schizophrenic patients. Large dose used at first to control acute symptoms, then reduced for maintenance which lasts for months, sometimes years.

  • affective disorders - in hypomania; in some cases of agitated and psychotic depression in conjunction with antidepressant treatment; in schizo-affective disorders - alone in the excited phase, with an antidepressant in the depressed phase.

  • acute symptomatic psychoses - and chronic brain syndromes with psychomotor agitation and paranoid symptoms - especially trifluoperazine.

  • in other patients, e.g. those with personality disorder or mental retardation, for symptomatic control of aggressive outbursts of agitation - the drug action is probably due to sedating side effects.

  • neuroses: to relieve anxiety and tension, as an alternative to minor tranquillisers especially when there is a high risk of dependency. Use with caution in short courses because of possible movement disorders.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.